ErbB-targeted treatments, such as afatinib, a pan-ErbB tyrosine kinase inhibitor, are potential therapeutic strategies to address unmet treatment needs in patients harboring NRG1 fusions.
A review article published in Annals of Oncology discusses the biology, detection, and incidence of NRG1 fusions, and the therapeutic role of afatinib and other ErbB-targeted agents in patients with cancer harboring NRG1 fusions.
This Publication Perspective video summarizes the review article on behalf of Dr Stephen Liu (Georgetown University Medical Center, Washington, D.C., USA) and his co-authors.
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
J Laskin, SV Liu, K Tolba et al.
Annals of Oncology 31(12), 1693–1703 (2020) DOI: 10.1016/j.annonc.2020.08.2335